

Carlos E DurÃ¡n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8068568/publications.pdf>

Version: 2024-02-01

10
papers

91
citations

1684188

5
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

126
citing authors

#	ARTICLE	IF	CITATIONS
1	Preprints in times of COVID19: the time is ripe for agreeing on terminology and good practices. BMC Medical Ethics, 2021, 22, 106.	2.4	29
2	Systematic review of cross-national drug utilization studies in Latin America: methods and comparability. Pharmacoepidemiology and Drug Safety, 2016, 25, 16-25.	1.9	13
3	Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2021, 45, 1-10.	1.1	13
4	A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project. Drug Safety, 2022, 45, 333.	3.2	10
5	EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients. BMJ: British Medical Journal, 2019, 367, l6017.	2.3	6
6	Essential Medicines in Universal Health Coverage: A Scoping Review of Public Health Law Interventions and How They Are Measured in Five Middle-Income Countries. International Journal of Environmental Research and Public Health, 2020, 17, 9524.	2.6	6
7	Sharp rise in the expenditures of targeted drugs in Ecuador: five-year (2010-2014) consumption of oncologic drugs in public and private hospitals. Journal of Pharmaceutical Health Services Research, 2018, 9, 175-182.	0.6	5
8	Pharmaceutical Policy in Ecuador. , 2017, , 221-236.		4
9	Potential negative impact of reputed regulators's™ decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis. PLoS ONE, 2021, 16, e0254585.	2.5	3
10	Policies influencing access to new targeted oncologic drugs in Ecuadorian hospitals: an interrupted time series analysis. Journal of Pharmaceutical Health Services Research, 2019, 10, 421-426.	0.6	1